Capital International Investors’s Revance Therapeutics, Inc. RVNC Stock Holding History

Capital International Investors’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,545,630	Closed	-$30.1M	–	464
2022 Q1	$30.1M	Hold	1,545,630	–	–	0.01%	381
2021 Q4	$25.2M	Hold	1,545,630	–	–	0.01%	394
2021 Q3	$43.1M	Hold	1,545,630	–	–	0.01%	359
2021 Q2	$45.8M	Hold	1,545,630	–	–	0.01%	365
2021 Q1	$43.2M	Buy	1,545,630 +383,730	+33%	+$10.6M	0.01%	347
2020 Q4	$32.9M	Hold	1,161,900	–	–	0.01%	361
2020 Q3	$29.2M	Hold	1,161,900	–	–	0.01%	351
2020 Q2	$28.4M	Hold	1,161,900	–	–	0.01%	331
2020 Q1	$17.2M	Hold	1,161,900	–	–	0.01%	329
2019 Q4	$18.9M	Buy	1,161,900 +836,900	+258%	+$13M	0.01%	323
2019 Q3	$4.22M	Hold	325,000	–	–	﹤0.01%	381
2019 Q2	$4.21M	Hold	325,000	–	–	﹤0.01%	378
2019 Q1	$5.12M	Hold	325,000	–	–	﹤0.01%	368
2018 Q4	$6.54M	Hold	325,000	–	–	﹤0.01%	354
2018 Q3	$8.08M	Buy	+325,000	New	+$8.84M	﹤0.01%	354

Other funds holding RVNC

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Capital International Investors's RVNC Position: Q2 2022 in Review

Capital International Investors sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2022, closing a stake of 1,545,630 shares — an estimated $30.1M sold.

Capital International Investors first reported a position in RVNC in Q3 2018 and held it in 15 quarters. The position peaked at $45.8M in Q2 2021. 161 funds tracked by Wall St. Rank hold RVNC as of Q2 2022.

Capital International Investors reported no remaining Revance Therapeutics, Inc. position as of Q2 2022 after selling out during the quarter.
Capital International Investors sold 1,545,630 Revance Therapeutics, Inc. shares in Q2 2022, an estimated $30.1M.
Capital International Investors first reported a position in Revance Therapeutics, Inc. in Q3 2018 and held it in 15 quarters.
Capital International Investors's Revance Therapeutics, Inc. position peaked at $45.8M in Q2 2021.
161 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2022.

Based on Capital International Investors's 13F filing for Q2 2022, filed 15 Aug 2022.